PubRank

S L Tucker

Author PubWeight™ 70.48‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Quantifying the position and steepness of radiation dose-response curves. Int J Radiat Biol 1997 2.02
2 Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 1997 2.01
3 Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med 1997 1.71
4 Damage and morbidity from pneumonitis after irradiation of partial volumes of mouse lung. Int J Radiat Oncol Biol Phys 1995 1.70
5 Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. Int J Radiat Oncol Biol Phys 1997 1.70
6 Comparison between normal tissue reactions and local tumor control in head and neck cancer patients treated by definitive radiotherapy. Int J Radiat Oncol Biol Phys 1996 1.53
7 Sequencing of chemotherapy and radiation in lymph node-negative breast cancer. Cancer J Sci Am 1999 1.48
8 The geographic relationships between physicians' residency sites and the locations of their first practices. Acad Med 1991 1.42
9 Incorporating an understanding of independent practice physician culture into hospital structure and operations. Hosp Health Serv Adm 1992 1.39
10 Biological effect of epidermal growth factor on the in vitro growth of human tumors. Cancer Res 1987 1.25
11 Extent and kinetics of recovery of occult spinal cord injury. Int J Radiat Oncol Biol Phys 2001 1.20
12 A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene 2010 1.17
13 Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of distant metastasis and survival. Radiother Oncol 1997 1.17
14 Long-term results with radiotherapy for Stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 2001 1.09
15 Genetic heterogeneity in saliva from patients with oral squamous carcinomas: implications in molecular diagnosis and screening. J Mol Diagn 2001 1.07
16 Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1989 1.04
17 Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. Hum Pathol 1996 1.03
18 Fibroblast radiosensitivity versus acute and late normal skin responses in patients treated for breast cancer. Int J Radiat Oncol Biol Phys 1995 0.99
19 Radiation-induced injury to the visual pathway. Radiother Oncol 1994 0.98
20 BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol 2001 0.95
21 Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J Clin Oncol 1986 0.94
22 Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. J Clin Oncol 2001 0.93
23 Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J 2001 0.92
24 Multiparametric in situ mRNA hybridization analysis to predict disease recurrence in patients with colon carcinoma. Am J Pathol 1996 0.91
25 Isoeffect models and fractionated radiation therapy. Int J Radiat Oncol Biol Phys 1987 0.91
26 Spatial heterogeneity of the volume effect for radiation pneumonitis in mouse lung. Int J Radiat Oncol Biol Phys 1997 0.91
27 Predominance of the metastatic phenotype in somatic cell hybrids of the K-1735 murine melanoma. Cancer Res 1991 0.89
28 The effect of tumor size on necrosis and polarographically measured pO2. Acta Oncol 1997 0.89
29 Prognostic value of serum beta-2 microglobulin in low-grade lymphoma. Ann Intern Med 1991 0.88
30 Comparison of two total body irradiation fractionation regimens with respect to acute and late pulmonary toxicity. Cancer 2001 0.88
31 A dose-surviving fraction curve for mouse colonic mucosa. Eur J Cancer Clin Oncol 1983 0.87
32 Residual radiation damage in murine lung assessed by pneumonitis. Int J Radiat Oncol Biol Phys 1988 0.86
33 Stage IV diffuse large-cell lymphoma: a long-term analysis. J Clin Oncol 1985 0.84
34 Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease. J Clin Oncol 1989 0.84
35 Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma: results of a matched cohort study. Cancer 1997 0.84
36 The prognostic significance of the biomarkers p21WAF1/CIP1, p53, and bcl-2 in laryngeal squamous cell carcinoma. Cancer 1998 0.83
37 DNA image analysis combined with routine cytology improves diagnostic sensitivity of common bile duct brushing. Cancer 2001 0.83
38 Correlation between lung fibrosis and radiation therapy dose after concurrent radiation therapy and chemotherapy for limited small cell lung cancer. Radiology 2001 0.83
39 Detection of micrometastatic tumor cells in bone marrow of breast carcinoma patients. J Surg Oncol 1991 0.83
40 Tests for the fit of the linear-quadratic model to radiation isoeffect data. Int J Radiat Oncol Biol Phys 1984 0.82
41 Combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1996 0.82
42 The relationship between functional assays of radiation response in the lung and target cell depletion. Br J Cancer Suppl 1986 0.82
43 Patient-reported genitourinary toxicity for long-term prostate cancer survivors treated with radiation therapy. Br J Cancer 2013 0.82
44 Tubular carcinoma of the breast. Predicting axillary nodal metastases and recurrence. Ann Surg 1996 0.81
45 Flexure dose: the low-dose limit of effective fractionation. Int J Radiat Oncol Biol Phys 1983 0.81
46 Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas. Int J Radiat Oncol Biol Phys 2000 0.81
47 Can modest escalations of dose be detected as increased tumor control? Int J Radiat Oncol Biol Phys 1992 0.81
48 Multivariate analysis of prognostic factors in regional cutaneous metastases of extremity melanoma. Cancer 1988 0.80
49 Stereotactic radiosurgery for brain metastases: results and prognostic factors. Int J Cancer 2000 0.80
50 Four methodologies to improve healthcare demand forecasting. Healthc Financ Manage 2001 0.79
51 Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data. Blood 1989 0.79
52 Protection of mouse jejunal crypt cells by WR-2721 after small doses of radiation. Int J Radiat Oncol Biol Phys 1986 0.79
53 Importance of radiation therapy for breast cancer patients treated with high-dose chemotherapy and stem cell transplant. Int J Radiat Oncol Biol Phys 2000 0.79
54 Numerical chromosomal changes in DNA hypodiploid solid tumors: restricted loss and gain of certain chromosomes. Cytometry 1999 0.79
55 Mathematical models for the cellular concentrations of cyclin and MPF. Biochem Biophys Res Commun 1992 0.79
56 Stages I and II diffuse large cell lymphomas: prognostic factors and long-term results with CHOP-bleo and radiotherapy. Blood 1991 0.79
57 Epidermal growth factor effect on serum-free growth of primary and metastatic human tumors. Int J Cell Cloning 1989 0.78
58 Time course of loss of residual radiation damage in murine skin assessed by retreatment. Int J Radiat Biol 1989 0.78
59 Expression of ERalpha and ERbeta in lobular carcinoma in situ. Histopathology 2007 0.78
60 Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas. Int J Radiat Oncol Biol Phys 2001 0.78
61 Small noncleaved cell lymphoma in adults: superior results for stages I-III disease. J Clin Oncol 1990 0.78
62 Radiation fractionation sensitivity of epiphyseal cartilage in a weanling rat model. Int J Radiat Oncol Biol Phys 1990 0.78
63 Is the mean inactivation dose a good measure of cell radiosensitivity? Radiat Res 1986 0.78
64 Clinical application of Percoll gradient-separated bone marrow. Bone Marrow Transplant 1987 0.78
65 Individualization of radiotherapy dose prescriptions by means of an in vitro radiosensitivity assay. Radiother Oncol 1998 0.78
66 Direct analysis of quantal radiation response data. Int J Radiat Biol Relat Stud Phys Chem Med 1986 0.77
67 Parameters of radiosensitivity. Radiat Res 1986 0.77
68 A model for regulation of the cell cycle incorporating cyclin A, cyclin B and their complexes. Cell Prolif 1994 0.77
69 Subdiaphragmatic stage I & II Hodgkin's disease: long-term follow-up and prognostic factors. Int J Radiat Oncol Biol Phys 1998 0.77
70 Interphase cytogenetics of renal cortical neoplasms. Correlation with DNA ploidy by flow cytometry. Am J Clin Pathol 1995 0.77
71 Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy. Int J Radiat Oncol Biol Phys 2001 0.77
72 Factors influencing the development of lung fibrosis after chemoradiation for small cell carcinoma of the lung: evidence for inherent interindividual variation. Int J Radiat Oncol Biol Phys 1998 0.76
73 Chromosomal and DNA ploidy characterization of salivary gland neoplasms by combined FISH and flow cytometry. Hum Pathol 1997 0.76
74 In vitro radiosensitivity and normal tissue damage. Radiother Oncol 2000 0.75
75 Comments on "Predicting normal tissue injury in radiation therapy". Int J Radiat Oncol Biol Phys 1991 0.75
76 Interleukin-1 dose, mouse strain, and end point as they affect protection of mouse jejunum. Radiat Res 1993 0.75
77 Introducing marketing as a planning and management tool. Hosp Health Serv Adm 1977 0.75
78 The role of the governing board of a distressed hospital. Top Health Care Financ 1990 0.75
79 Effects and interactions of epidermal growth factor, insulin, hydrocortisone, and estradiol on the cloning of human tumor cells. Int J Cell Cloning 1985 0.75
80 Integrating planning and marketing activities in hospitals. Health Care Plann Mark 1981 0.75
81 Hospital market share: the declining share of small players in the market. Health Care Manage Rev 1990 0.75
82 Hospitals in the USA. World Hosp 1978 0.75
83 Analysis must precede adoption of competitive strategies. Hospitals 1982 0.75
84 Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis. Cancer 1994 0.75
85 Physicians' needs for medical specialist support. Health Care Strateg Manage 1986 0.75
86 New options in direct analysis of dose-response data. Int J Radiat Biol 1990 0.75
87 Establishment of an outpatient surgery program using existent hospital facilities. Case Stud Health Adm 1980 0.75
88 What makes an effective CEO? The board's perspective. Trustee 1989 0.75
89 The hospital governing board's quest for 'supermanager'. Healthc Exec 1991 0.75
90 Hematologic recovery after central lymphatic irradiation for patients with stage I-III follicular lymphoma. Cancer 2001 0.75
91 Perception of body odor-an overlooked consequence of long-term gastrointestinal and urinary symptoms after radiation therapy for prostate cancer. J Cancer Surviv 2013 0.75
92 An applicant's checklist for assessing executive positions. Hosp Prog 1978 0.75
93 The significance of molecular response of follicular lymphoma to central lymphatic irradiation as measured by polymerase chain reaction for t(14;18)(q32;q21). Int J Radiat Oncol Biol Phys 2001 0.75
94 Nucleotide excision repair proteins and their importance for radiation-enhanced transfection. Int J Radiat Biol 2003 0.75
95 Healthcare marketing: maximizing your competitive position. Health Serv Manager 1981 0.75
96 Marketing: applications in a military health care setting. Mil Med 1997 0.75
97 Optimal design of multifraction assays of colony survival in vivo. Radiat Res 1983 0.75
98 Stage I Hodgkin disease: radiation therapy and chemotherapy at the University of Texas M. D. Anderson Cancer Center, 1996-1997. Radiology 1998 0.75
99 Salvage central lymphatic irradiation in follicular lymphomas following failure of chemotherapy: a feasibility study. Int J Radiat Oncol Biol Phys 1999 0.75
100 The integration of strategic decision support systems in health administration education. J Health Adm Educ 1996 0.75
101 Does your hospital really care what you think? Med Econ 1982 0.75
102 Applying stakeholder analysis to health care administration education. J Health Adm Educ 1994 0.75
103 Prognostic implications of DNA index in patients with stage III cutaneous melanoma. Am J Surg 1993 0.75
104 Personality patterns of health care and industry CEOs: similarities and differences. Health Care Manage Rev 1996 0.75
105 Strategic market planning. Top Health Care Financ 1988 0.75
106 Marketing research tools for hospital management. Tex Hosp 1980 0.75